Summary of Key Points from the Conference Call Company Overview - **Company**: 新为医疗 (New Medical) - **Industry**: Neurointervention and Brain-Computer Interface (BCI) Core Insights and Arguments 1. **Product Development**: New Medical's invasive brain-computer interface (BCI) collects brain signals via intravascular electrode stents, with plans to start small-scale exploratory clinical trials by the end of 2026, primarily for post-stroke motor function recovery [2][3][5] 2. **Market Potential**: Approximately 1.5 to 2 million new stroke cases occur annually in China, with an estimated 4 to 5 million patients needing rehabilitation training in the next three years, representing a significant potential user base for BCI products [2][5] 3. **Technical Advantages**: The invasive BCI technology offers advantages over non-invasive methods, including less trauma and higher signal strength, although the precise wall-adhesion technology for electrode stents remains a key challenge [2][6] 4. **Financial Projections**: For the first half of 2025, the company expects profits of 15 to 18 million, with a full-year target of 30 million and revenue goals of 380 million, aiming for a long-term gross margin of 65% and a net margin of 15% to 20% [2][20] 5. **Strategic Planning**: The company aims to achieve profitability by 2025, with annual revenue growth of 30% over the next three to five years, leveraging collective procurement and product launches to capture market share [4][27] Additional Important Insights 1. **Clinical Research and Collaboration**: New Medical has partnered with Nankai University for clinical applications in stroke recovery, focusing on motor function restoration [5][18] 2. **Regulatory Environment**: The company is closely monitoring policy developments from regulatory bodies to facilitate product registration and inclusion in medical insurance reimbursement systems [10][12] 3. **Market Expansion**: New Medical is actively pursuing overseas market expansion, currently limited by FDA and EU certification processes [15][21] 4. **Product Pipeline**: The company plans to submit for regulatory review of its self-expanding drug-eluting stent by Q4 2025, with expectations for approval within a year [17] 5. **Industry Trends**: The collective procurement policy has significantly increased the market share of domestic neurointervention products, with projected growth in ischemic and hemorrhagic surgery volumes of 15%-20% and 10%-15%, respectively, in 2025 [4][22] Conclusion - New Medical is positioned to capitalize on the growing demand for neurointervention and BCI technologies, with a robust product pipeline and strategic partnerships aimed at enhancing recovery for stroke patients. The company is focused on achieving profitability and expanding its market presence while navigating regulatory challenges and industry dynamics.

Core Insights - The 2025 Oriental Cerebrovascular Disease Conference showcased the global launch of the Lattice NEXT, a new generation "headless" mechanical balloon mesh stent system by Aiko Medical, emphasizing innovation in neurointerventional solutions [2][4][18]. Group 1: Product Innovation - The Lattice NEXT stent has gained significant market share in a short time, receiving international acclaim for its innovative design and clinical applications [4][18]. - The stent's "headless" design enhances operational safety by reducing the risk of damage to branch vessels during procedures [11][18]. - The integration of a mechanical balloon with cobalt-chromium materials in the Lattice NEXT stent improves distal vascular compatibility and safety [7][12]. Group 2: Clinical Applications - Clinical data indicates that the Lattice series has been successfully applied to a wide range of cases, from routine to complex aneurysms, demonstrating superior performance in challenging scenarios [14][35]. - The stent's design allows for effective treatment of complex aneurysms, with a high follow-up cure rate observed in various clinical settings [7][35]. - The introduction of intelligent selection tools for stent sizing simplifies preoperative planning, particularly in complex anatomical cases [13][18]. Group 3: Expert Opinions - Experts have praised the Lattice NEXT for its design, which enhances intraoperative safety and provides more options for treating complex aneurysms [18][29]. - The mechanical balloon system has been highlighted for its ability to ensure proper stent placement even in tortuous vascular paths, showcasing its critical value in challenging cases [34][36]. - The collaborative development between R&D teams and clinical practitioners has been emphasized as a key factor in the rapid innovation and effectiveness of the Lattice products [15][29].

Group 1 - The Hang Seng Index rose by 0.15% to 24,777 points, while the Hang Seng Tech Index fell by 0.82% with a trading volume of 1,476 billion HKD in the morning session [1] - Yuejiang Technology surged over 18%, reaching a new high, after launching an affordable humanoid robot and being included in the Stock Connect list, ranking first in China's collaborative robot sector with a global market share of 13.0% [1] - Horizon Robotics-W increased by over 5% ahead of its annual performance announcement, with multiple catalysts expected in the short term according to analysts [1] Group 2 - Mixue Group's stock rose by 5.25%, hitting a new high since its listing, with institutions suggesting the company may enjoy a valuation premium [2] - Laopuyin Gold's stock increased by 6.48%, with an earnings surprise expected to show a potential profit growth of up to 2.6 times for the full year [3] - Xirui's stock rose by 7.58% after being included in the Stock Connect list, as it is a general aircraft manufacturer under AVIC [4] Group 3 - Duodian Smart's stock surged over 10% post-earnings, despite reporting a year-on-year increase in shareholder losses of approximately 2.7 times [5] - Microneuroscience's stock rose by 5.99%, with expectations of net profit growth potentially doubling for the full year [5] - High伟 Electronics increased by 6.78%, with institutions anticipating an increase in mobile phone subsidies ahead of its earnings release [5] Group 4 - China National Chemical Corporation's stock fell by 4.65% due to a significant drop in urea selling prices, leading to a year-on-year halving of its annual profit [6] - China Unicom's stock dropped over 4% post-earnings, despite a 10% year-on-year increase in net profit, with a reported loss in the fourth quarter on a non-recurring basis [7] - XPeng Motors' stock fell over 6% after reporting a narrowed adjusted net loss of 1.39 billion CNY in the fourth quarter [7]